Diridavumab

Names

[ Name ]:
Diridavumab

Biological Activity

[Description]:

Diridavumab is a monoclonal anti-HA stalk antibody. Diridavumab stabilizes the prefusion HA structure and prevents pH-dependent fusion of cellular and viral membranes in endosomes. Diridavumab can be used in research of H2 influenza virus[1].

[Related Catalog]:

Signaling Pathways >> Anti-infection >> Influenza Virus

Research Areas >> Infection

[In Vitro]

Diridavumab (CR6261; 500 μg/mL) 分别以 39.4 μg/mL 和 176.8 μg/mL 的浓度中和 AA60 和 Sw06[1]。

[In Vivo]

Diridavumab (CR6261; 1.7-15 mg/kg; i.p.; 携带 H2 流感病毒的 BALB/c 小鼠) 以剂量依赖性方式保护小鼠免受致命的 H2 流感病毒的侵害[1]。 Animal Model: BALB/c mice with H2 influenza virus[1] Dosage: 1.7, 5, or 15 mg/kg Administration: Intraperitoneal injection Result: Prevented mortality and decreased the percent weight loss. Decreased viral load, altered antigen distribution, and reduced the severity of airway inflammation.

[References]

[1]. Sutton TC, et, al. In Vitro Neutralization Is Not Predictive of Prophylactic Efficacy of Broadly Neutralizing Monoclonal Antibodies CR6261 and CR9114 against Lethal H2 Influenza Virus Challenge in Mice. J Virol. 2017 Nov 30;91(24):e01603-17.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.